Drug Profile
INS 115644
Alternative Names: INS115644; latrunculin BLatest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Wisconsin Alumni Research Foundation
- Developer Merck & Co
- Class Antiglaucomas; Heterocyclic bicyclo compounds; Macrolides; Small molecules; Thiazolidines
- Mechanism of Action Actin modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Glaucoma
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in Glaucoma in USA (Ophthalmic, Drops)
- 16 May 2011 Inspire Pharmaceuticals has been acquired by Merck & Co
- 09 Nov 2006 Inspire Pharmaceuticals has filed an IND with the FDA in the US for glaucoma